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Background: Coronary artery disease (CAD) is a major public health problem for developed and developing countries and is the single 
leading cause of death worldwide.
Objectives: There is very few evidence regarding changes of both serum Lectin-like oxidized-low density lipoprotein receptor-1 (LOX-1) 
and adiponectin in patients with CAD accompanied with metabolic syndrome (MS). Here we aimed to evaluate serum levels of LOX-1 and 
adiponectin in patients with CAD accompanied with MS.
Patients and Methods: Thirty patients with coronary artery disease without metabolic syndrome, 30 patients with coronary artery 
disease and metabolic syndrome, 30 ones with metabolic syndrome and 30 healthy subjects were enrolled. For all subjects, a questionnaire 
was filled to collect data, and peripheral blood samples were collected aseptically from the antecubital vein to measure serum Lectin-like 
oxidized-low density lipoprotein receptor-1 and adiponectin levels by enzyme-linked immunosorbent assay.
Results: Serum LOX-1 level was highest in CAD + MS group; the difference between control and disease groups was statistically significant 
(P < 0.001). Adiponectin level had the lowest value in CAD + MS group; the difference between control and disease groups was statistically 
significant (P < 0.05). No significant differences were observed in serum Lectin-like oxidized-low density lipoprotein receptor-1and 
adiponectin in patients with different ages and gender. Serum LOX-1 level was changed negatively and linearly (R2 = 0.721) correlated with 
adiponectin level in different groups.
Conclusions: Patient with CAD and MS had higher risk than those with only CAD because of lipid and glucose metabolism abnormalities. 
Combination measurements of serum LOX-1 and adiponectin levels may be helpful to evaluate the severity of CAD together with MS.
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1. Background
Proinflammatory oxidized low-density lipoprotein (ox-
LDL) is the unifying link between lipid accumulation and 
inflammation in the vessel wall and ox-LDL in plasma and 
within atherosclerotic lesions is strongly associated with 
CAD and vulnerable plaques (1). Endothelial dysfunction 
elicited by ox-LDL and its receptor has been shown to play a 
crucial role in the pathogenesis of atherosclerosis. LOX-1, a 
novel ox-LDL receptor with 50 kDa type II transmembrane 
glycoprotein comprising 273 amino acids, was cloned on 
bovine aortic endothelial cells in 1997 (2). LOX-1 supports 
binding, internalization and proteolytic degradation of 
ox-LDL when cells accepted stimulus from proinflamma-
tory cytokine. Increased LOX-1 mRNA and protein expres-
sion in endothelial cells, macrophages, vascular smooth 
muscle cells and platelets are stimulated by angiotensin 
II and proinflammatory cytokine such as tumor necrosis 
factor alpha, which causes apoptosis, decreases nitric ox-
ide synthase expression and stimulates reactive oxygen 
species (3). Several reports revealed that elevated serum 
levels of ox-LDL is associated with CAD (4). Soluble form of 
LOX-1 can be found on the cell surface into culture media. 
It has been reported that serum LOX-1 level is specifically 
elevated in acute coronary syndromes. Peak values of LOX-
1 are observed earlier than those of Troponin T in acute 
coronary syndromes (5). Recently, many authors have 
shown that LOX-1 can be used as a good new biomarker in 
the diagnosis and prognosis of patients with coronary ar-
tery disease (6). Ox-LDL is also associated with MS and total 
ox-LDL levels were higher in subjects with MS than those 
without it (7). Circulating amount of oxidation-related 
moiety on low density lipoprotein has been shown to be 
effective to predict or diagnose MS and cardiovascular dis-Md Sayed AS et al.
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eases (8). Combination of serum adiponectin level and MS 
is closely associated with CAD (9). Nevertheless, rare stud-
ies revealed the effect of LOX-1 in predicting MS.
Adipose tissue-derived factors such as free fatty acids, 
several cytokines including tumor necrosis factor alpha, 
interleukins, leptin, and adiponectin are the characters of 
MS. Increasing attention has been paid to the direct vascu-
lar effects of plasma proteins that originate from adipose 
tissue, especially adiponectin. Adiponectin is the most 
abundant adipokine secreted by adipose cells, which may 
couple regulation of insulin sensitivity with energy me-
tabolism. Adiponectin is a 30-kDa protein containing an 
N-terminal collagenous domain and a C-terminal globular 
domain. Decreased plasma adiponectin levels is observed 
in patients with diabetes, MS, and CAD (10). Although the 
mechanisms underlying antiinflammatory properties 
of adiponectin are not well understood, adiponectin an-
tiinflammatory and antiatherogenic properties may be 
related, in part, to its ability to stimulate production of ni-
tric oxide from vascular endothelium (11). Low plasma adi-
ponectin level is significantly correlated with endothelial 
dysfunction and could be a useful marker for early-stage 
atherosclerosis. Very recently, it has been demonstrated 
that a low adiponectin level combined with an advanced 
age, male gender, diabetes mellitus (DM) and hyperten-
sion (HT) is directly associated with multivessel coronary 
atherosclerosis disease (12). Plasma concentrations of adi-
ponectin are significantly lower in patients with acute cor-
onary syndromes than those with stable angina and the 
control group (13). In addition, adiponectin is associated 
with a decreased risk of coronary heart disease events in 
the same cohort men with diabetes (14). Low adiponectin 
levels are also associated with MS (15). 
MS is a complex of interrelated risk factors for cardio-
vascular disease (16). At a clinical level, patients with MS 
need to be identified to reduce their multiple risk factors. 
Nonetheless, patients with MS are at twice risk of develop-
ing cardiovascular disease over the next 5 to 10 years as in-
dividuals without the syndrome. MS diagnosis according 
to the World Health Organization criteria could be made 
based on several markers of insulin resistance together 
with some additional risk factors, including obesity, hyper-
tension, high triglyceride level, reduced high-density lipo-
protein cholesterol level, or microalbuminuria. However, 
combined serum markers such as LOX-1 and adiponectin 
in CAD accompanied with MS are still unknown.
2. Objectives
Our study aimed to examine serum LOX-1and adiponec-
tin levels in patients with CAD and MS.
3. Patients and Methods
3.1. Study Approval
In this clinical study, all participants signed a written 
consent prior to their enrollment, which was undertaken 
with the approval of the local ethics committee of the Car-
diology Department of Xiangya Hospital (Xiangya Medi-
cal College, Central South University, code-10533). Follow-
ing ethical approval, permission obtained to perform the 
study and access to the patients and their records.
3.2. Study Population
Patients admitted to Cardiology Department of Xiangya 
Hospital, Central South University, China, were enrolled 
in this study from 8 August 2009 to 30 June 2010. Thirty 
patients with CAD with a mean age of 66 years (23 males 
and 7 females), 30 patients with CAD and MS with a mean 
age of 61 years (13 males and 17 females), and 30 patients 
with MS with a mean age of 53 years (23 males, 7 females) 
were enrolled as disease groups. For control group, 30 
healthy subjects with a mean age of 51 years (22 males, 
8 females) were enrolled from the Xiangya Medical Cen-
ter. Both the patients and controls were selected from 
the Han ethnic population born and currently living in 
Changsha City of Hunan Province, People’s Republic of 
China. The main purpose of this study was to compare 
the LOX-1 and Adiponectin levels between patients with 
CAD + MS and those with only CAD; here we used the 
two-sample mean comparison formula to calculate the 
sample size. From the literatures, the level of Adiponec-
tin in patients with CAD and MS was about 7.0 μg/mL, and 
the level of Adiponectin in patients with CAD without MS 
was 11.0 μg/mL, and the standard deviation (σ) was almost 
4.0 μg/mL, the difference between the two populations (δ) 
was 4.0 μg/mL. Let α = 0.05 and β = 0.10 and the number 
calculated as 23.
From the inspection results of patients in this study, the 
level of LOX-1 in patients with CAD and MS was about 200 
pg/mL, and the level of LOX-1 in patients with CAD without 
MS was 400 pg/mL, and the standard deviation (σ) was al-
most 100 pg/mL, let the difference between two popula-
tions (δ) was 200 pg/mL and the number calculated as 12.
In the actual operation, sample size in each group was 
increased to 30 to reduce the sample bias. Inclusion cri-
teria for control group were; age of 30-75 yours, physical 
and clinical examination report with normal findings; 
no history of hypertension or not taking any antihy-
pertensive medications and diabetes, and no acute or 
chronic disease condition; all blood and biochemical 
reports such as complete blood count, lipid profile, liver Md Sayed AS et al.
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function, and kidney function had normal results; echo-
cardiography and ultrasonography reports had normal 
findings. Selection of patients with CAD was based on 
clinical diagnosis. Based on coronary angiography find-
ings regarding left anterior descending artery, left cir-
cumflex artery and right coronary artery, patients were 
considered to have CAD if coronary artery stenosis (at 
least one of them) was equal to or more than 50%. Ac-
cording to the American Heart Association, coronary 
artery stenosis was divided into less than or equal to 
25%, 50%, 75%, 90%, 99%, 100% (occlusion). Symptoms of 
CAD were recorded and classified according to the Ca-
nadian Cardiovascular Society and New York Heart As-
sociation. Patients with acute coronary syndrome or 
acute myocardial infarction or CAD patients with acute 
or chronic heart failure were excluded in this group. 
Selection of patients with MS was based on clinical di-
agnosis. According to the International Diabetes Federa-
tion and the National Heart, Lung, and Blood Institute, 
there are five risk factors for MS as dysglycemia, raised 
blood pressure, elevated triglyceride levels, low levels of 
high-density lipoprotein cholesterol and obesity (par-
ticularly central adiposity). Patients were diagnosed as 
MS if three of the above five mentioned risk factors were 
present. Patients with CAD were excluded in this group. 
3.3. Data Collection
For all the study subjects, an standardized question-
naire was filled to collect data and comprehensive physi-
cal and medical examinations were performed after 12 
hours fasting in the morning, such as height (m), weight 
(kg), blood pressure (mmHg) and body mass index (BMI). 
3.4. Biochemical Measurements
Peripheral blood sample was aseptically collected 
from the antecubital vein for biochemical measure-
ments. Fasting blood glucose, total cholesterol, triglyc-
erides, low-density lipoprotein cholesterol and high-
density lipoprotein cholesterol, liver function, kidney 
function and high-sensitivity C-reactive protein (hs-
CRP) were evaluated using an automatic analyzer (Hi-
tach75, Tokyo, Japan).
3.5. Measurements of Serum LOX-1 and Adiponectin
Another four mL of blood was also taken and placed in 
ethylenediaminetetraacetic acid tubes, centrifuged at 
1000 rpm for 5 minutes, then the serum was collected 
and stored at -80°C for further measurements. The con-
centrations of LOX-1 and adiponectin were determined 
by commercial ELISA kit (Shanghai Yueyan Biology Tech-
nology Co, China) and the color changes were measured 
spectrophotometrically at a wavelength of 450 nm by 
comparing the O.D. of the samples to the standard curve. 
Here we used purified Human LOX-1 and adiponectin an-
tibody respectively.
3.6. Statistical Analysis
Data was analyzed and graphs were constructed by 
statistical program, SPSS-16.0 and Microsoft Excel. T-test, 
One-way ANOVA and Student-Newman-Keuls post hoc 
test, chi-square test and Bonferroni post hoc test, Kruskal-
Wallis H test and Student-Newman-Keuls post hoc test, 
Pearson’s correlation and multiple linear regressions 
were used. Values in figure and table were shown as mean 
± SD and proportion. P < 0.05 was considered as statisti-
cally significant.
4. Results
4.1. General Clinical Information and Biochemical 
Indicators
General clinical information and biochemical values 
were shown in Table 1. Systolic and diastolic blood pres-
sure in CAD + MS group (142 ± 9 mmHg/82 ± 7 mmHg), MS 
group (136 ± 6 mmHg/74 ± 7 mmHg) and CAD group (129 ± 
10 mmHg/77 ± 7 mmHg) were higher than control group 
(124 ± 8 mmHg/72 ± 5 mmHg), respectively; the differ-
ences were statistically significant (P < 0.05). Body mass 
index in CAD + MS group (27.2 ± 1 kg/m2), MS group (25.6 
± 1 kg/m2) and CAD group (23.7 ± 1.3 kg/m2) were higher 
than control group (21.1 ± 1.5 kg/m2), which were signifi-
cantly different (P < 0.05). Serum triglyceride (2.1 ± 1.4 
mmol/L), fasting blood sugar (6.2 ± 0 mmol/L), Aspartate 
amino-transferase (23.5 ± 4.8 U/L), Alanine amino-trans-
ferase (21.2 ± 4 U/L), creatinine (89.3 ± 16 mg/L), uric acid 
(314.7 ± 55.1 mmol/L) and hs-CRP (12.0 ± 8.5 mg/L) levels 
were higher in CAD + MS group compared with control 
group. Triglyceride (0.84 ± 0.3 mmol/L), fasting blood 
sugar (4.5 ± 0.3 mmol/L), aspartate amino-transferase 
(11.2 ± 3.6 U/L), alanine amino-transferase (14.5 ± 4.5 U/L), 
creatinine (71.0 ± 9.8 mg/L), uric acid (251.9 ± 42 mmol/L) 
and hs-CRP (0.7 ± 0.8mg/L), were significantly different 
(P < 0.05). The CAD group had higher blood urea nitro-
gen (5.5 ± 0.9 mmol/L) level than the CAD + MS (5.3 ± 1 
mmol/L) group, MS group (4.8 ± 1.4 mmol/L) and the con-
trol group (3.9 ± 0.6 mmol/L), which were significantly 
different (P < 0.05).
4.2. Role of Gender Variation in LOX-1 and 
Adiponectin Level in Different Groups
Serum LOX-1 and adiponectin levels of male and female 
participants in different groups were shown in Table 2. 
Serum LOX-1 levels in different groups were as follows; 
control group: male (86.6 ± 8.2 pg/mL), female (88.7 ± 
9.9 pg/mL); CAD group: male (195.0 ± 41.5 pg/mL), female 
(200.0 ± 39.4 pg/mL); MS group: male (137.2 ± 11.5 pg/mL), 
female (149.7 ± 18.8 pg/mL) and CAD + MS groups: male 
(464.4 ± 100.8 pg/mL), female (414.3 ± 107.5 pg/mL). Adipo-
nectin levels in different groups were as follows; control 
group: male (515.1 ± 30.0 µg/L), female (499.1 ± 25.4 µg/L); Md Sayed AS et al.
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CAD group: male (370.5 ± 20.9 µg/L), female (368.0 ± 21.4 
µg/L); MS group: male (456.9 ± 23.8 µg/L), female (436.7 
± 23.1 µg/L) and CAD + MS group: male (264.8 ± 20 µg/L), 
female (262.8 ± 31.4 µg/L). No significant differences were 
observed in plasma LOX-1 and adiponectin levels between 
male and female participants in each group (P > 0.05).
4.3. Role of Age Variation in LOX-1 and Adiponectin 
Levels in Different Groups
LOX-1 and adiponectin levels of CAD and MS patients in 
different age groups were shown in Table 3. Serum LOX-1 
levels in different groups were as follows: control group: 
≤ 50 years (85.5 ± 5.5 pg/mL), ≤ 70 years (87.8 ± 11.5 pg/
mL), > 70 years (92.5 ± 6.8 pg/mL); CAD group: ≤ 50 years 
(232.4 ± 8.1 pg/mL), ≤ 70 years (178.6 ± 28.6 pg/mL), > 70 
years (220.5 ± 46.3 pg/mL ); MS group: ≤ 50 years (139.4 
± 11.1 pg/mL), ≤ 70 years (142.9 ± 18.3 pg/mL), > 70 years 
(137.4 ± 12.4 pg/mL) and CAD + MS group: ≤ 50 years 
(342.7 ± 68.7 pg/mL), ≤ 70 years (448.4 ± 84.4 pg/mL), > 
70 years (500.9 ± 155.9 pg/mL). Serum adiponectin levels 
in different groups were as follows; control group: ≤ 50 
years (532.5 ± 23.6 µg/L), ≤ 70 years (491.9 ± 15.3 µg/L), > 
70 years (478.7 ± 4.7 µg/L); CAD group: ≤ 50 years (379.4 ± 
26.5 µg/L), ≤ 70 years (369.4 ± 21.9 µg/L), > 70 years (369.0 
± 19.2 µg/L); MS group: ≤ 50 years (454.3 ± 28.3 µg/L), ≤ 
70 years (447.4 ± 23.7 µg/L), >70 years (454.4 ± 23.5 µg/L) 
and CAD + MS group: ≤ 50 years (245.2 ± 39.7 µg/L), ≤ 70 
years (268.3 ± 22.4 µg/L), > 70 years (268.4 ± 16.6 µg/L). Se-
rum LOX-1 and adiponectin levels of CAD and MS patients 
in different age groups between control and diseased 
groups were not statistically significant (P > 0.05). 
4.4. Serum LOX-1 Level in Different Groups
Serum LOX-1 levels in different groups were shown 
in Figure 1. The highest LOX-1 level was found in CAD + 
MS group (435.9 ± 105.9 pg/mL), followed by CAD group 
(196.2 ± 40.4 pg/mL) and MS group (140.9 ± 15 pg/mL). It 
was 87.1 ± 8.5 pg/mL in control group. The differences 
between control and diseased groups were statistically 
significant (P < 0.001).
4.5. Serum Adiponectin Level in Different Groups
Serum adiponectin levels in different groups were 
shown in Figure 2. The lowest adiponectin level was 
found in CAD + MS (263.6 ± 26.6 µg/L) group, followed by 
CAD (369.9 ± 20.7 µg/L) group and MS (450.8 ± 25 µg/L) 
group. It was 510.9 ± 29.3 µg/L in control group. The differ-
ences between control and diseased groups were statisti-
cally significant (P < 0.05, P < 0.001).
4.6. Association Between LOX-1 and Adiponectin 
Levels in Different Groups
Serum LOX-1 and adiponectin associations in different 
groups were shown in Figure 3. Serum LOX-1 level was 
changed negatively and linearly (R2 = 0.721) correlated 
with adiponectin level in different groups; the Pearson's 
correlation coefficient (r) was -0.849.
4.7. Association Between Adiponectin Level and In-
fluencing Factors 
The association between adiponectin level and influ-
encing factors was analyzed using multiple linear step-
wise regressions method (α in = 0.05, α out = 0.10) con-
sidering adiponectin as the dependent variable, with age 
(≤ 50 years as 1, ≤ 70 years as 2, > 70 years as 3), gender 
(male as 1, female as 2), LOX-1, BMI, SBP, DBP, TG, TC, HDL-C, 
LDL-C, FBS, AST, ALT, BUN, Cr, UA, hs-CRP as independent 
variables. Results showed in Table 4, LOX-1, AST, BMI, TC, 
gender, BUN, DBP affected the Adiponectin level. Multiple 
correlation coefficient (R), coefficient of determination 
(R2), adjusted coefficient of determination, P values of 
this regression were 0.912, 0.832, 0.822, and < 0.001, re-
spectively. We also judged the sample meet the condi-
tions of multiple linear regressions through the stan-
dardized residual plot were shown in Figure 4.
Table 1 . General Clinical Information and Biochemical indicators of Patients and Control Groups a,b
Parameters Control MS CAD CAD + MS P Value
Case, No. 30 30 30 30
Age, y 51 ± 11 53 ± 11 66 ± 9 61 ± 11 < 0.001
Gender, %
Male 73 77 77 43 0.026
BMI, kg/m2 21.1 ± 1.5 25.6 ± 1 23.7 ± 1.3 27.2 ± 1.3 < 0.001
SBP, mmHg 124 ± 8 136 ± 6 129 ± 10 142 ± 9 < 0.001
DBP, mmHg 72 ± 5 74 ± 7 77 ± 7 82 ± 7 < 0.001
TG, mmol/L 0.84 ± 0.3 2.3 ± 1.2 1.7 ± 1.6 2.1 ± 1.4 < 0.001
TC, mmol/L 4.2 ± 0.7 4.9 ± 1.1 4.1 ± 1.3 4.5 ± 1.1 0.015
HDL-C, mmol/L 1.7 ± 0.3 1.4 ± 0.3 1.4 ± 0.8 1.3 ± 0.4 0.001
LDL-C, mmol/L 1.9 ± 0.6 2.4 ± 0.9 2.3 ± 1.0 2.3 ± 1.0 0.156Md Sayed AS et al.
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FBS, mmol/L 4.5 ± 0.3 5.9 ± 0.6 5.0 ± 0.7 6.2 ± 0.7 < 0.001
AST, U/L 11.2 ± 3.6 18.3 ± 4.3 21.2 ± 5.4 23.5 ± 4.8 < 0.001
ALT, U/L 14.5 ± 4.5 19.0 ± 4.0 20.9 ± 5.6 21.2 ± 4 < 0.001
BUN, mmol/L 3.9 ± 0.6 4.8 ± 1.4 5.5 ± 0.9 5.3 ± 1 < 0.001
Cr, mg/L 71.0 ± 9.8 83.5 ± 10.6 85.8 ± 14.1 89.3 ± 16 < 0.001
UA, mmol/L 251.9 ± 42 307.0 ± 60.0 285.7 ± 53.5 314.7 ± 55.1 < 0.001
hs-CRP, mg/L 0.7 ± 0.8 1.7 ± 2.9 7.2 ± 9.8 12.0 ± 8.5 < 0.001
a  Results were mean ± SD. Values in a same row with different superscripts were significantly different (P < 0.05). 
b  Abbreviations: ALT; alanine transaminase, AST; aspartate aminotransferase, BMI; body mass index, BUN; blood urine nitrogen, CAD; coronary 
artery disease, Cr; creatinine, DBP; Diastolic blood pressure, FBS; fasting blood sugar, LDL; low density lipoprotein, HDL; high density lipoprotein, MS; 
metabolic syndrome, SBP; systolic blood pressure, TG; triglyceride, TC; total cholesterol, UA; uric acid.
Table 2.  LOX-1 and Adiponectin Levels of Male and Female in Different Groups a,b
Control MS CAD CAD + MS
LOX-1 (pg/mL)
Male 86.6 ± 8.2 137.2 ± 11.5 195.0 ± 41.5 464.4 ± 100.8
Female 88.7 ± 9.9 149.7 ± 18.8 200.0 ± 39.4 414.3 ± 107.5
P-value 0.557 0.033 0.779 0.205
Adiponectin (µg/L)
Male 515.1 ± 30.0 456.9 ± 23.8 370.5 ± 20.9 264.8 ± 20
Female 499.1 ± 25.4 436.7 ± 23.1 368.0 ± 21.4 262.8 ± 31.4
P-value 0.191 0.041 0.786 0.839
a  Values were mean ± SD.
b  CAD; coronary artery disease, MS; metabolic syndrome.
Table 3.  LOX-1 and Adiponectin Levels in Different Groups With Different Ages a,b
Control MS CAD CAD + MS
LOX-1, pg/mL
≤ 50 y 85.5 ± 5.5 139.4 ± 11.1 232.4 ± 8.1 342.7 ± 68.7
≤ 70 y 87.8 ± 11.5 142.9 ± 18.3 178.6 ± 28.6 448.4 ± 84.4
> 70 y 92.5 ± 6.8 137.4 ± 12.4 220.5 ± 46.3 500.9 ± 155.9
P-value 0.420 0.766 0.018 0.039
Adiponectin, µg/L
≤ 50 y 532.5 ± 23.6 454.3 ± 28.3 379.4 ± 26.5 245.2 ± 39.7
≤ 70 y 491.9 ± 15.3 447.4 ± 23.7 369.4 ± 21.9 268.3 ± 22.4
> 70 y 478.7 ± 4.7 454.4 ± 23.5 369.0 ± 19.2 268.4 ± 16.6
P-value < 0.001 0.763 0.809 0.165
a Values were mean ± SD. The difference of LOX-1 between different age groups in CAD + MS and CAD groups was assessed using Kruskal-Wallis H and 
Student-Newman-Keuls post hoc tests.
b  CAD; coronary artery disease, MS; metabolic syndrome.
Table 4.  Multiple Linear Regression Regarding Adiponectin Level and Influencing Factors a
b sb b’ t P Value
Constant 802.645 56.451 14.218 < 0.001
LOX-1, pg/mL -0.352 0.038 -0.531 -9.355 < 0.001
AST, U/L -3.043 0.766 -0.204 -3.792 < 0.001
BMI, kg/m2 -6.214 2.066 -0.166 -3.008 0.003
TC, mmol/L 12.752 3.508 0.147 3.636 < 0.001
Gender -26.878 8.280 -0.133 -3.246 0.002
BUN, mmol/L -9.355 3.649 -0.114 -2.564 0.012
DBP, mmHg -1.226 0.533 -0.100 -2.301 0.023
a  Abbreviations: AST; aspartate aminotransferase, BMI; body mass index, BUN; blood urine nitrogen, DBP; Diastolic blood pressure, TC; total cholesterol.Md Sayed AS et al.
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Figure 1. The highest LOX-1 level was found in CAD + MS group (435.9 ± 
105.9 pg/mL), which was followed by CAD group (196.2 ± 40.4 pg/mL) and 
MS group (140.9 ± 15 pg/mL). In control group it was (87.1 ± 8.5 pg/mL). 
The result shows that the difference between control and diseased groups 
were statistically significant (P < 0.001).
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Figure 2. The lowest adiponectin level was found in CAD + MS (263.6 ± 26.6 
µg/L) group, which was followed by CAD (369.9 ± 20.7 µg/L) group and MS 
(450.8 ± 25 µg/L) group. In control group it was (510.9 ± 29.3 µg/L). The re-
sult shows that the difference between control and diseased groups were 
statistically significant (P < 0.05, P < 0.001).
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Figure 3. Plasma LOX-1 level was changed negatively and linearly (R2 = 
0.721) correlated with adiponectin level in different groups.
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Figure 4. This study’s standardized residual plot showed that most points 
are located between ± 2 standard deviation and distributed uniformly 
around the 0 reference line, and it proved that these data basically met 
the conditions of multiple linear regression. But we should pay attention 
to the two suspicious points which located between -2 standard deviation 
and -3 standard deviation.
5. Discussion
CAD is the most common type of heart disease, which is 
usually caused by atherosclerosis. Increased plasma level 
of low-density lipoprotein is a well-known risk factor for 
endothelial dysfunction and atherosclerosis. The pro-ath-
erosclerotic potential of low density lipoprotein may even 
increase after oxidative modification to ox-LDL, whose 
uptake by macrophage scavenger receptors is thought to 
be a key process in the formation of foam cells, as the hall-
mark of atherosclerotic lesions (17). In human atheroscle-
rotic lesions, LOX-1 is expressed prominently by intimal 
smooth muscle cells and lipid-laden macrophages in ad-
vanced plaques. Furthermore, LOX-1 plays an important 
role in oxidized-low density lipoprotein induced apop-
tosis of vascular smooth muscle cells and production of 
matrix metalloproteinases, which might be directly as-
sociated with plaque rupture. LOX-1 is also expressed on 
the surface of activated platelets, which may also be in-
volved in thrombus formation after plaque rupture (18). 
Although LOX-1 is expressed at very low levels in healthy 
endothelium, several lines of evidence support a role of 
LOX-1 in the pathogenesis of atherosclerosis (19). Mean-
while, LOX-1 expression is increased in hypertension, 
diabetes mellitus, hyperlipidemia, chronic renal failure, 
acute coronary syndromes and the highest expression 
of LOX-1 is found in atherosclerotic lesions (20). Several 
research groups have analyzed the association between 
LOX-1 gene polymorphisms and CAD and a higher risk of 
acute myocardial infarction (21). A community-based co-
hort study, measured apolipoprotein B and soluble LOX-1 
using ELISA with recombinant LOX-1 and monoclonal an-
ti-apolipoprotein B antibody and with two monoclonal 
antibodies against LOX-1, respectively; higher Lectin-like 
oxidized-low density lipoprotein index [Lectin-like oxi-
dized-low density lipoprotein index apolipoprotein B × 
soluble LOX-1] values were associated with increased risk Md Sayed AS et al.
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of coronary heart disease (22). Generally LOX-1 level has a 
positive association with vascular inflammation. In the 
present study, the highest LOX-1 level was found in CAD + 
MS group, followed by CAD group and MS group. It was the 
lowest in control group. Our finding of gradually increas-
ing serum LOX-1 concentration with increasing severity of 
CAD was consistent with some other studies (5, 21-23). Most 
studies investigated the impact of LOX-1 on the incidence 
of CAD, but in addition to CAD, we tried to find out the role 
of LOX-1 in CAD plus MS and only MS patients. Our finding 
suggests CAD plus MS group as the highest risk group for 
acute myocardial infarction; the severity increased more 
than two folds compared to CAD group and more than 
four folds compared to control group. Whereas, patients 
in MS group had LOX-1 expression more than one fold as 
compared to control group.
Adiponectin is one of the important active cytokines se-
creted from adipose tissue, which regulates glucose and 
lipid homeostasis, energy metabolism, and poses anti-
inflammatory activity (24). Dysregulation of adiponectin 
has been implicated in metabolic X syndrome, atheroscle-
rosis, obesity, hypertension and CAD (25). Atherosclerotic 
endothelial dysfunction, particularly in the early disease 
stages, is primarily due to dysregulation of endothelial 
nitric oxide synthase enzymatic activity and inactivation 
of nitric oxide through oxidative stress (26). Reduced bio-
availability of nitric oxide is involved in the initiation, 
progression and complications of atherosclerosis. Adipo-
nectin induces endothelial nitric oxide synthase activa-
tion and nitric oxide production in endothelial cells. Adi-
ponectin reduces reactive oxygen species production as 
well as improving endothelial function in aortas of ApoE 
KO mice (27). Adiponectin can potentially inhibit all the 
molecular pathways of atherosclerosis, including mono-
cyte adhesion to endothelial cells by adhesion molecules, 
ox-LDL uptake of macrophages through scavenger recep-
tors and proliferation of migrated smooth muscle cells by 
the action of platelet-derived growth factors and heparin-
binding epidermal growth factor. Therefore, it seems that 
adiponectin is predominantly beneficial and high levels 
of circulating adiponectin confer vascular protection (28). 
Adiponectin has beneficial roles for the vascular system 
and it has been proven that decreased plasma levels of 
adiponectin are associated with coronary atherosclerosis 
(29). Low serum adiponectin levels are significantly corre-
lated with endothelial dysfunction. Hypoadiponectinemia 
correlates significantly and independently with CAD. Se-
rum concentrations of adiponectin in patients with acute 
coronary syndromes are significantly lower than those 
with stable angina and the control group. Individuals 
with adiponectin concentrations in the highest quintile 
compared with the lowest quintile have a decreased risk 
of myocardial infarction (30). In addition, adiponectin was 
associated with a decreased risk of coronary heart disease 
events in the same cohort men with diabetes. However, ad-
iponectin has a negative association with vascular inflam-
mation (31). In this study, we found that adiponectin level 
is significantly different between diseased and control 
group. The lowest adiponectin level was found in CAD + MS 
group, which was followed by CAD group and MS group. 
It was the highest in control group. Our results indicated 
that decreasing serum adiponectin level is associated with 
increasing severity of CAD. According to our findings, CAD 
plus MS group was the most vulnerable group followed by 
CAD group and MS group as compared to control group. 
Similar findings were found in many other studies (10, 13, 
26, 29, 30, 32).
According to Arita et al. women had about 40% higher 
circulating levels of adiponectin than men, but in our 
study adiponectin levels of male and female between con-
trol and diseased groups were not statistically different 
(P = 0.839). We determined the association between LOX-1 
and adiponectin in CAD and CAD + MS patients. Our study 
showed that plasma LOX-1 level was changed negatively 
and linearly (R2 = 0.721) correlated with adiponectin level 
in different groups. Our results also showed that LOX-1, 
AST, BMI, TC, gender, BUN, DBP affected Adiponectin level. 
Multiple correlation coefficient (R), coefficient of deter-
mination (R2), adjusted coefficient of determination and 
P value of this regression were 0.912, 0.832, 0.822 and < 
0.001, respectively.
Furthermore, low adiponectin levels were associated 
with MS. MS has received increasing attention because it 
represents an important risk for cardiovascular diseases 
(32). MS is a compilation of associated risk factors, increas-
es the risk of CAD, which can progress to artery occlusion 
(33). Our finding also suggests that low level of adiponec-
tin and high level of LOX-1 were related to MS. Our findings 
are in agreement with some others (33, 34). There are very 
few studies regarding the evaluation of these two param-
eters. According to our knowledge, we determined and 
evaluated this inverse association in patients with CAD 
and CAD + MS for the first time.
In conclusion, we found that serum levels of LOX-1 are 
increased in CAD, but this increase is more obvious in pa-
tients with MS. Serum levels of adiponectin are decreased 
in CAD and the decrease is more remarkable in patients 
with MS. Our findings showed for the first time that using 
combination of these two important serum parameters 
may be an effective method to evaluate the severity of car-
diovascular disease accompanied with metabolic disease 
such as CAD plus MS. Patients with CAD and MS seem to 
have a higher risk than those with only CAD because of 
both lipid and glucose metabolism abnormalities. The re-
sult may not be novel but of clinical importance. More pa-
tients should be enrolled and more cardiovascular events 
such as cardiovascular mortalities and cardiovascular hos-
pitalization rates should be assessed in future studies to 
evaluate the effect of LOX-1 and adiponectin.
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